stockrow
Monday 9 November 2026
Export CMPX’s income statement to Excel — free account
Compass Therapeutics, Inc.
CMPXCompass Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $850,000.00.
- EPS
- +7.14%
- Free cash flow
- −26.1%
Quarter to June 2026, against a year earlier
0.76
0.08
+11.76%
Follow CMPX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | — | — | — | — | 7 | 45 | +588.3% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | — | 0.00 | +100.0 pt | ||||||
| EBT | — | 0 | 0 | (35) | (29) | (82) | (39) | (42) | (49) | (66) | (73) | +156.9% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (5,808.82) | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | 0 | (35) | (29) | (82) | (39) | (42) | (49) | (66) | (73) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.73) | (5.19) | (0.96) | (1.31) | (0.37) | (0.33) | (0.36) | (0.42) | (0.40) | (7.6%) | ||||||
| Cash flow | — | — | (0.65) | (4.74) | (0.87) | (0.31) | (0.32) | (0.32) | (0.33) | (0.31) | (0.30) | (9.9%) | ||||||
| Capex | — | — | 0.00 | (0.07) | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.65) | (4.81) | (0.87) | (0.34) | (0.32) | (0.32) | (0.33) | (0.31) | (0.30) | (9.9%) | ||||||
| Book value | — | 0.00 | (1.63) | (17.73) | 1.30 | 2.23 | 1.73 | 1.17 | 0.91 | 1.25 | 0.89 | n/m | ||||||
| Shares, m | — | — | 52 | 7 | 31 | 63 | 105 | 127 | 137 | 158 | 175 | +17.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | 1.59 | — | 0.86 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (1.74) | — | 0.57 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (34) | (32) | (27) | (20) | (34) | (41) | (45) | (49) | (56) | +5.5% | |||||
| Capex | — | — | (2) | 0 | 0 | (1) | 0 | 0 | 0 | 0 | 0 | (46.6%) | ||||||
| Free cash flow | — | — | (34) | (32) | (27) | (21) | (34) | (41) | (45) | (49) | (56) | +5.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 0 | (8) | 16 | 40 | 136 | 179 | 146 | 124 | 196 | 165 | n/m | |||||
| Net debt | — | — | 145 | (10) | (38) | (145) | (187) | (152) | (127) | (209) | (180) | n/m | ||||||
| Shareholders’ equity | — | 0 | (85) | (119) | 40 | 140 | 182 | 149 | 125 | 197 | 166 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | 0.00 | (1,469.39) | (228.69) | (71.70) | (79.92) | (22.20) | (23.84) | (33.22) | (36.94) | (47.87) | (36.9) pt | |||||
| ROIC | — | 0.00 | (0.03) | 0.00 | (789.04) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | 100.72 | 0.08 | 58.55 | 75.01 | (91.30) | (24.38) | (25.74) | (36.07) | (41.29) | (56.66) | (142.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 31 | 24 | 26 | 32 | 35 | — | — | +3.1% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | — | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Jun 2024 · fundamentals updated 2 Nov 2026
Compass Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| YARW Yarrow Bioscience, Inc | $147.2M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| CMPX Compass Therapeutics, Inc. | $136.7M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | |
| CUE Cue Biopharma, Inc. | $136.1M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TARA Protara Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SPRB Spruce Biosciences, Inc. | $133.8M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MENS Jyong Biotech Ltd. | $133.6M | — | — | — | — | — | — | — | Compare |
| PDSB PDS Biotechnology Corporation | $129.2M | — (loss-making) | — | — | n/m | +69.32% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $119.2M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +11.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CHRS Coherus Oncology, Inc. | $119.0M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| Median of peers | $133.7M | — | — | +39.53% | — | −28.10% | 70.35% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
18.70%
Entities affiliated with Tang Capital Management, LLC
9.50%
Entities affiliated with OrbiMed Advisors, LLC
8.50%
Carl L. Gordon, Ph.D., CFA
8.50%
Entities affiliated with Suvretta Capital Management, LLC
7.80%
Entities affiliated with Vivo Opportunity, LLC
5.30%
Thomas J. Schuetz, MD, Ph.D.
5.20%
BlackRock, Inc.
5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement